AOD-9604 vs. Matrixyl

Category

Growth

Cosmetic

CAS no.

221231-10-3

214047-00-4

Molecular weight

1815.09 g/mol

802.06 g/mol

Half-life

0.4 h

Sequence

AOD-9604

AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.

Matrixyl

KTTKS is a fragment of the procollagen I sequence and appears to be part of a feedback mechanism in fibroblasts: elevated concentrations signal intact collagen synthesis and downregulate new synthesis, while low concentrations stimulate it. In cell-culture studies, stimulation of collagen types I/III, elastin, fibronectin and glycosaminoglycans has been documented. The palmitoyl modification is intended to improve skin penetration; effect at the site of action (dermal fibroblasts) depends on permeation.

Highest evidence

Studies

3

5

of which in humans

2

2

Effects recorded

3

3

Open conflicts

1

0

Documented adverse events

1

1